[1]
|
中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251.
|
[2]
|
Zhang, X., Mu, R., Wang, X., Xu, C., Duan, T., An, Y., et al. (2015) The Impact of Rheumatoid Arthritis on Work Capacity in Chinese Patients: A Cross-Sectional Study. Rheumatology, 54, 1478-1487.
https://doi.org/10.1093/rheumatology/kev014
|
[3]
|
Zhu, H., Li, R., Da., Z., Bi, L., Li, X., Li, Y., et al. (2018) Remission Assessment of Rheumatoid Arthritis in Daily Practice in China: A Cross-Sectional Observational Study. Clinical Rheumatology, 37, 597-605.
https://doi.org/10.1007/s10067-017-3850-z
|
[4]
|
Smolen, J.S., Aletaha, D., Bijlsma, J.W., et al. (2010) Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 69, 631-637. https://doi.org/10.1136/ard.2009.123919
|
[5]
|
Hodge, J.A., Kawabata, T.T., Krishnaswami, S., Clark, J.D., Telliez, J.B., Dowty, M.E., et al. (2016) The Mechanism of Action of Tofacitinib—An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 34, 318-328.
|
[6]
|
Villarino, A.V., Kanno, Y. and O’Shea, J.J. (2015) Mechanisms of Jak/STAT Signaling in Immunity and Disease. Journal of Immunology, 194, 21-27. https://doi.org/10.4049/jimmunol.1401867
|
[7]
|
Tamai, M., Kawakami, A., Tanaka, F., Miyashita, T., Nakamura, H., Iwanaga, N., et al. (2006) Significant Inhibition of TRAIL-Mediated Fibroblast-Like Synovial Cell Apoptosis by IFN-Gamma through JAK/STAT Pathway by Translational Regulation. Journal of Laboratory and Clinical Medicine, 147, 182-190.
https://doi.org/10.1016/j.lab.2005.12.001
|
[8]
|
Carrara, G., Bortoluzzi, A., Sakellariou, G., Silvagni, E., Zanetti, A., Govoni, M., et al. (2019) Risk of Hospitalisation for Serious Bacterial Infections in Patients with Rheumatoid Arthritis Treated with Biologics. Analysis from the RECord linkage On Rheumatic Disease Study of the Italian Society for Rheumatology. Clinical and Experimental Rheumatology, 37, 60-66.
|
[9]
|
Nakayamada, S., Kubo, S., Iwata, S. and Tanaka, Y. (2016) Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs, 30, 407-419. https://doi.org/10.1007/s40259-016-0190-5
|
[10]
|
Tanaka, Y., Takeuchi, T., Yamanaka, H., Nakamura, H., Toyoizumi, S. and Zwillich, S. (2015) Efficacy and Safety of Tofacitinib as Monotherapy in Japanese patients with Active Rheumatoid Arthritis: A 12-Week, Randomized, Phase 2 Study. Modern Rheumatology, 25, 514-521. https://doi.org/10.3109/14397595.2014.995875
|
[11]
|
Fleischmann, R., Cutolo, M., Genovese, M.C., Lee, E.B., Kanik, K.S., Sadis, S., et al. (2012) Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) or Adalimumab Monotherapy versus Placebo in Patients with Active Rheumatoid Arthritis with an Inadequate response to Disease-Modifying Antirheumatic Drugs. Arthritis & Rheumatism, 64, 617-629. https://doi.org/10.1002/art.33383
|
[12]
|
Kremer, J.M., Cohen, S., Wilkinson, B.E., Connell, C.A., French, J.L., Gomez-Reino, J., et al. (2012) A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone. Arthritis & Rheumatism, 64, 970-981. https://doi.org/10.1002/art.33419
|
[13]
|
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. (2012) Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 367, 495-507. https://doi.org/10.1056/NEJMoa1109071
|
[14]
|
Burmester, G.R., Blanco, R., Charles-Schoeman, C.H., Wollenhaupt, J., Zerbini, C., Benda, B., et al. (2013) Tofacitinib (CP-690,550) in Combination with MTX in Patients with Active Rheumatoid Arthritis with an Inadequate Response to Tumour Necrosis Factor Inhibitors: A Randomized Phase III Trial. Lancet, 381, 451-460.
https://doi.org/10.1016/S0140-6736(12)61424-X
|
[15]
|
Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al. (2013) Tofacitinib in Combination with Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis: A Randomized Trial. Annals of Internal Medicine, 159, 253-261.
https://doi.org/10.7326/0003-4819-159-4-201308200-00006
|
[16]
|
Van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. (2013) Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis Receiving MTX Twelve-Month Data from a Twenty-Four-Month Phase III Randomized Radiographic Study. Arthritis & Rheumatism, 65, 559-570. https://doi.org/10.1002/art.37816
|
[17]
|
Van Vollenhoven, R., Fleischmann, R., Cohen, S., Lee, E.B., García Meijide, J.A., Wagner, S., et al. (2012) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. New England Journal of Medicine, 367, 508-519.
https://doi.org/10.1056/NEJMoa1112072
|
[18]
|
Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., et al. (2014) Tofacitinib versus MTX in Rheumatoid Arthritis. New England Journal of Medicine, 370, 2377-2386. https://doi.org/10.1056/NEJMoa1310476
|
[19]
|
Strand, V., Kremer, J., Wallenstein, G., Kanik, K.S., Connell, C., Gruben, D., et al. (2015) Effects of Tofacitinib Monotherapy on Patient-Reported Outcomes in a Randomized Phase 3 Study of Patients with Active Rheumatoid Arthritis and Inadequate Responses to DMARDs. Arthritis Research & Therapy, 17, Article No. 307.
|
[20]
|
Strand, V., Burmester, G.R., Zerbini, C.A., Mebus, C.A., Zwillich, S.H., Gruben, D., et al. (2015) Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Trial. Arthritis Care & Research, 67, 475-483. https://doi.org/10.1002/acr.22453
|
[21]
|
Strand, V., Kremer, J.M., Gruben, D., Krishnaswami, S., Zwillich, S.H. and Wallenstein, G.V. (2017) Tofacitinib in Combination with Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Randomized Controlled Trial. Arthritis Care & Research, 69, 592-598.
https://doi.org/10.1002/acr.23004
|
[22]
|
Strand, V., Lee, E.B., Fleischmann, R., Alten, R.E., Koncz, T., Zwillich, S.H., et al. (2016) Tofacitinib versus Methotrexate in Rheumatoid Arthritis: Patient-Reported Outcomes from the Randomised Phase III ORAL Start Trial. RMD Open, 2, Article ID: e000308. https://doi.org/10.1136/rmdopen-2016-000308
|
[23]
|
Fleischmann, R., Mysler, E., Hall, S., Kivitz, A.J., Moots, R.J., Luo, Z., et al. (2017) Effificacy and Safety of Tofacitinib Monotherapy, Tofacitinib with MTX, and Adalimumab with MTX in Patients with Rheumatoid Arthritis (ORAL Strategy): A Phase IIIb/IV, Double-Blind, Head-to-Head, Randomized Controlled Trial. Lancet, 390, 457-468.
https://doi.org/10.1016/S0140-6736(17)31618-5
|
[24]
|
Yamanaka, H., Tanaka, Y., Takeuchi, T., Sugiyama, N., Yuasa, H., Toyoizumi, S., et al. (2016) Tofacitinib, an Oral Janus Kinase Inhibitor, as Monotherapy or with Background Methotrexate, in Japanese Patients with Rheumatoid Arthritis: An Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 18, 34.
|
[25]
|
Cohen, S.B., Tanaka, Y., Mariette, X., Curtis, J.R., Lee, E.B., Nash, P., et al. (2017) Long-Term Safety of Tofacitinib for the Treatment of Rheumatoid Arthritis up to 8.5 Years: Integrated Analysis of Data from the Global Clinical Trials. Annals of the Rheumatic Diseases, 76, 1253-1262. https://doi.org/10.1136/annrheumdis-2016-210457
|
[26]
|
Wollenhaupt, J., Lee, E.B., Curtis, J.R., Silverfield, J., Terry, K., Soma, K., et al. (2019) Safety and Efficacy of Tofacitinib for up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 21, Article No. 89. https://doi.org/10.1186/s13075-019-1866-2
|
[27]
|
Curtis, J.R., Xie, F., Yun, H., Bernatsky, S. and Winthrop, K.L. (2016) Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 75, 1843-1847. https://doi.org/10.1136/annrheumdis-2016-209131
|
[28]
|
Winthrop, K.L., Melmed, G.Y., Vermeire, S., Long, M.D., Chan, G., Pedersen, R.D., et al. (2018) Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases, 24, 2258-2265.
https://doi.org/10.1093/ibd/izy131
|
[29]
|
Moghoofei, M., Mostafaei, S., Ashraf-Ganjouei, A., Kavosi, H. and Mahmoudi, M. (2018) HBV Reactivation in Rheumatic Diseases Patients under Therapy: A Meta-Analysis. Microbial Pathogenesis, 114, 436-443.
https://doi.org/10.1016/j.micpath.2017.12.014
|
[30]
|
Lau, C.S., Chia, F., Harrison, A., Hsieh, T.-Y., Jain, R., Jung, S.M., et al. (2015) APLAR Rheumatoid Arthritis Treatment Recommendations. International Journal of Rheumatic Diseases, 18, 685-713.
https://doi.org/10.1111/1756-185X.12754
|
[31]
|
Mori, S. and Fujiyama, S. (2015) Hepatitis B Virus Reactivation Associated with Antirheumatic Therapy: Risk and Prophylaxis Recommendations. World Journal of Gastroenterology, 21, 10274-10289.
https://doi.org/10.3748/wjg.v21.i36.10274
|
[32]
|
van Vollenhoven, R., Lee, E.B., Strengholt, S., Mojcik, C., Valdez, H., Krishnaswami, S., et al. (2019) Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis. Arthritis & Rheumatology, 71, 685-695. https://doi.org/10.1002/art.40780
|
[33]
|
Xie, F., Yun, H., Bernatsky, S. and Curtis, J.R. (2016) Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis & Rheumatology, 68, 2612-2617. https://doi.org/10.1002/art.39761
|
[34]
|
Curtis, J.R., Lee, E.B., Kaplan, I.V., Kwok, K., Geier, J., Benda, B., et al. (2016) Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Development Programme. Annals of the Rheumatic Diseases, 75, 831-841. https://doi.org/10.1136/annrheumdis-2014-205847
|
[35]
|
Baecklund, E., Iliadou, A. and Askling, J. (2006) Association of Chronic Inflammation, Not Its Treatment, with Increased Lymphoma Risk in Rheumatoid Arthritis. Arthritis & Rheumatism, 54, 692-701.
https://doi.org/10.1002/art.21675
|
[36]
|
Simon, T.A., Thompson, A., Gandhi, K.K., Hochberg, M.C. and Suissa, S. (2015) Incidence of Malignancy in Adult Patients with Rheumatoid Arthritis: A Meta-Analysis. Arthritis Research & Therapy, 17, Article No. 212.
https://doi.org/10.1186/s13075-015-0728-9
|
[37]
|
Sivaraman, P. and Cohen, S.B. (2017) Malignancy and Janus Kinase Inhibition. Rheumatic Disease Clinics of North America, 43, 79-93. https://doi.org/10.1016/j.rdc.2016.09.008
|
[38]
|
Verden, A., Dimbil, M., Kyle, R., Overstreet, B. and Hoffman, K.B. (2018) Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Drug Safety, 41, 357-361. https://doi.org/10.1007/s40264-017-0622-2
|
[39]
|
Claxton, L., Jenks, M., Taylor, M., Wallenstein, G., Mendelsohn, A.M., Bourret, J.A., et al. (2016) An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of Managed Care & Specialty Pharmacy, 22, 1088-1102. https://doi.org/10.18553/jmcp.2016.22.9.1088
|
[40]
|
Claxton, L., Taylor, M., Soonasra, A., Bourret, J.A. and Gerber, R.A. (2018) An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis after Methotrexate or after 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Journal of Managed Care & Specialty Pharmacy, 24, 1010-1017. https://doi.org/10.18553/jmcp.2018.17220
|
[41]
|
Tian, L., Xiong, X., Guo, Q., Chen, Y., Wang, L., Dong, P., et al. (2020) Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. PharmacoEconomics, 38, 1345-1358.
https://doi.org/10.1007/s40273-020-00961-z
|